Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Aim Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$8,031,508

661 payments

Through program year 2025, Aim Trials LLC is reported as receiving $8,031,508 in research payments, across 661 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $791,081 96
2024 Research $2,048,695 128
2023 Research $1,939,315 87
2022 Research $1,368,864 91
2021 Research $656,399 110
2020 Research $806,459 82
2019 Research $420,695 67

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $3,457,167 62 payments
  2. Allergan Inc. $1,144,755 139 payments
  3. Pfizer Inc. $822,624 120 payments
  4. AbbVie, Inc. $745,817 98 payments
  5. Corium, Inc. $601,250 23 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $465,910 9 payments
  7. ITI, Inc. $212,854 78 payments
  8. BioXcel Therapeutics, Inc. $118,846 9 payments
  9. GlaxoSmithKline, LLC. $115,039 21 payments
  10. Biohaven Pharmaceuticals, Inc. $68,278 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $3,101,160 51 payments
  2. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $359,384 21 payments
  3. A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $329,222 6 payments
  4. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $307,297 25 payments
  5. An Efficacy and Safety Study w/ Azstarys in Children With ADHD $274,572 5 payments
  6. A Phase 3 Master Protocol to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults at High Risk of Severe RSV Disease $226,521 14 payments
  7. Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD $196,253 9 payments
  8. A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) $175,169 7 payments
  9. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (Trial 405-201-00014) $163,281 1 payment
  10. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder $157,754 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record